TriangleNCT01459653 · OUTCOME
Characteristics of Clusters: Hemoglobin Study Start
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- g/dL
- Interval / dispersion
- Standard Deviation
- Time frame
- Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.
What was measured
Objective 7: To identify different latent clusters of end-stage cancer patients receiving chemotherapy and being treated with EP2006 for the treatment or primary or secondary prophylaxis of FN using statistical data-mining techniques to profile patients based on medical history, concomitant comorbid conditions, and current clinical status.
Analysis population: A two-group solution converged and the groups differentiated on key baseline variables. However, the group sizes were too unevenly distributed for further analysis with the "high risk group" comprised of only 3.0% of the evaluable sample. Only patients with data in each group are analyzed for hemoglobin at study start.
Groups in this outcome
EP2006 - Group 1
Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
EP2006 - Group 2
Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
| Group | Source count |
|---|---|
| EP2006 - Group 1 | 1175 |
| EP2006 - Group 2 | 43 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| EP2006 - Group 1 | 12.35 | 1.80 | Not reported | Not reported | Not reported |
| EP2006 - Group 2 | 11.82 | 1.86 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 1.80
- value
- 12.35
- group Id
- OG001
- spread
- 1.86
- value
- 11.82
- denoms
- counts
- group Id
- OG000
- value
- 1175
- group Id
- OG001
- value
- 43
- units
- Participants
- description
- Objective 7: To identify different latent clusters of end-stage cancer patients receiving chemotherapy and being treated with EP2006 for the treatment or primary or secondary prophylaxis of FN using statistical data-mining techniques to profile patients based on medical history, concomitant comorbid conditions, and current clinical status.
- dispersion Type
- Standard Deviation
- groups
- description
- Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
- id
- OG000
- title
- EP2006 - Group 1
- description
- Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
- id
- OG001
- title
- EP2006 - Group 2
- param Type
- MEAN
- population Description
- A two-group solution converged and the groups differentiated on key baseline variables. However, the group sizes were too unevenly distributed for further analysis with the "high risk group" comprised of only 3.0% of the evaluable sample. Only patients with data in each group are analyzed for hemoglobin at study start.
- reporting Status
- POSTED
- time Frame
- Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.
- title
- Characteristics of Clusters: Hemoglobin Study Start
- type
- SECONDARY
- unit Of Measure
- g/dL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice